Karyopharm Therapeutics Inc.
Close on Oct 19, 2026
- Market cap
- $10.01K
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 2, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | Before market open | $33.40M | $-2.32 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | Before market open | $35.10M | $-1.24 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 12, 2026 | Before market open | $34.10M | $-5.71 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 3, 2025 | Before market open | $44.00M | $-3.82 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | Before market open | $37.90M | $-4.32 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 12, 2025 | After market close | $30.00M | $-2.77 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 13, 2025 | Before market open | $30.00M | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 5, 2024 | Before market open | $38.80M | $-0.26 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 8, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 13, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| R&D and selling, general and administrative (SG&A) expenses | full year 2026 | $230.00M to $245.00M | Maintained |
| Total revenue | full year 2026 | $130.00M to $150.00M | Raised |
| U.S. XPOVIO net product revenue | full year 2026 | $115.00M to $130.00M | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Karyopharm Therapeutics filed with the SEC
Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission
Results of operations · EX-99.1 to Form 8-K
Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment
Results of operations · EX-99.1 to Form 8-K
Karyopharm’s Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
On Today’s Call Welcome Brendan Strong, SVP, Investor Relations
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Karyopharm Announces $30 Million Private Placement with RA Capital
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
Results of operations · EX-99.1 to Form 8-K
Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026
Results of operations · Other events · EX-99.1 to Form 8-K
Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress
Results of operations · EX-99.1 to Form 8-K
Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends
Material agreement · Results of operations · New financial obligation · Unregistered share sale · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress
Results of operations · EX-99.1 to Form 8-K
Confidential Investor Presentation July 2025 ©2025 KARYOPHARM THERAPEUTICS INC. | CONFIDENTIAL & PROPRIETARY
Regulation FD disclosure · EX-99.1 to Form 8-K
Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress
Results of operations · EX-99.1 to Form 8-K
Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives
Results of operations · EX-99.1 to Form 8-K
Karyopharm Therapeutics Provides Endometrial Cancer Program Update
Regulation FD disclosure · EX-99.1 to Form 8-K
Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress
Results of operations · EX-99.1 to Form 8-K
Targeting Disease at the Nuclear Pore
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
Results of operations · EX-99.1 to Form 8-K
Targeting Disease at the Nuclear Pore
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Targeting Disease at the Nuclear Pore
Results of operations · EX-99.1 to Form 8-K
Targeting Disease at the Nuclear Poreh3
Results of operations · EX-99.1 to Form 8-K
Targeting Disease at the Nuclear Pore
Results of operations · EX-99.1 to Form 8-K
Targeting Disease at the Nuclear Pore
Results of operations · EX-99.1 to Form 8-K
Targeting Disease at the Nuclear Pore
Results of operations · EX-99.1 to Form 8-K
Targeting Disease at the Nuclear Pore
Results of operations · EX-99.1 to Form 8-K
Targeting Disease at the Nuclear
Results of operations · EX-99.1 to Form 8-K
Targeting Disease at the Nuclear Pore
Results of operations · EX-99.1 to Form 8-K
Targeting Disease at the Nuclear Pore
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Targeting Disease at the Nuclear Pore
Results of operations · EX-99.1 to Form 8-K
Targeting Disease at the Nuclear Pore
Results of operations · EX-99.1 to Form 8-K
Targeting Disease at the Nuclear Pore
Results of operations · EX-99.1 to Form 8-K
Targeting Disease at the Nuclear Pore
Results of operations · Other events · EX-99.1 to Form 8-K
Targeting Disease at the Nuclear Pore
Results of operations · Other events · EX-99.2 to Form 8-K
Targeting Disease at the Nuclear Pore
Results of operations · EX-99.1 to Form 8-K
Targeting Disease at the Nuclear Pore
Results of operations · EX-99.1 to Form 8-K